Share with Colleagues
Previous EBM Focus Issues
Become a DynaMed Reviewer
DynaMed Free Trial
Send Comment to Editor
Physicians: .25 AMA PRA Category I CreditsTM
Family Physicians: .25 Prescribed credits
Nurse Practitioners: .25 Contact hours
Release Date: April 16, 2014
Expiration Date: April 16, 2015
Estimated Completion Time: 15 minutes
There is no fee for this activity.
To Receive Credit
In order to receive your certificate of participation, you should read the information about this activity, including the disclosure statements, review the entire activity, take the post-test, and complete the evaluation form. You may then follow the directions to print your certificate of participation. To begin, click the CME icon at the end of the article.
Upon successful completion of this educational program, the reader should be able to:
1. Discuss the significance of this article as it relates to your clinical practice.
2. Be able to apply this knowledge to your patient's diagnosis, treatment and management.
Alan Ehrlich, MD - Assistant Clinical Professor in Family Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA; Senior Deputy Editor, DynaMed, Ipswich, Massachusetts, USA
Michael Fleming, MD, FAAFP - Assistant Clinical Professor of Family Medicine and Comprehensive Care, LSU Health Science Center School of Medicine, Shreveport, Louisiana, USA; Assistant Clinical Professor of Family Medicine, Department of Family and Community Medicine, Tulane University Medical School, New Orleans, Louisiana, USA; Chief Medical Officer, Amedisys, Inc. & Antidote Education Company
Dr. Ehrlich, Dr. Fleming, DynaMed Editorial Team members, and the staff of Antidote Education Company have disclosed that they have no relevant financial relationships or conflicts of interest with commercial interests related directly or indirectly to this educational activity.
No commercial support has been received for this activity.
ACCME: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Antidote Education Company and EBSCO Publishing. Antidote is accredited by the ACCME to provide continuing medical education for physicians. Antidote Education Company designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
AAFP: Enduring Material activity, DynaMed EBM Focus, has been reviewed and is acceptable for up to 13 Prescribed credits by the American Academy of Family Physicians. AAFP certification begins March 7, 2012. Term of approval is for one year from this date with the option of yearly renewal. Each EBM Focus is worth .25 Prescribed credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AANP: This program is approved for 0.25 contact hour of continuing education by the American Academy of Nurse Practitioners.
Program ID: 1304159V
Last week, the DynaMed EBM Focus highlighted evidence from 2 new randomized trials evaluating oral antiviral therapy in patients with chronic HCV genotype 1 infection. The original version erroneously omitted part of a sentence describing previous approval of the agent sofosbuvir by the U.S. Food and Drug Administration. Please see a corrected version below, and refer to the Hepatitis C topic in DynaMed for further information.
The DynaMed Editorial Team
Last week 676 journal articles were evaluated via DynaMed's Systematic Literature Surveillance and summaries of 279 articles were added to DynaMed content.
Based on criteria for selecting "articles most likely to change clinical practice," one article was selected by the DynaMed Editorial Team.
When to start treatment for chronic hepatitis C is a controversial and uncertain area. In patients with HCV and advanced liver disease, treatment that achieves a sustained virologic response is associated with lower rates of liver-related morbidity and mortality, and treatment is generally recommended. For patients without advanced liver disease, guidelines suggest individualized decision-making. In this group, the absolute rates of adverse clinical events are low with a long time to develop, so the relative benefit of early treatment is uncertain compared to monitoring and starting treatment later as needed.
For patients in whom therapy is being considered, the combination of recombinant human interferon alfa as weekly injections and weight-based oral ribavirin has historically been a mainstay of treatment. However, both agents are limited by established adverse reactions: interferon is associated with various flu-like symptoms, depression, and cytopenia, while ribavirin is associated with hemolytic anemia, fatigue, pruritus, and rash. A recent joint treatment guideline from the American Society for the Study of Liver Disease and the Infectious Diseases Society of America includes recommendations for newer direct-acting antiviral agents (AASLD/IDSA 2014 Feb PDF); however, these recommendations were based on small phase 2 studies. Now, 2 large phase 3 trials have evaluated an oral fixed-dose combination of an HCV nonstructural protein 5A inhibitor (ledipasvir) and a nucleotide polymerase inhibitor (sofosbuvir) in adults with chronic HCV genotype 1 infection.
The first trial (ION-1) included previously untreated patients, whereas the second trial (ION-2) included patients previously treated with peginterferon plus ribavirin (53% also received a protease inhibitor) who had not had a sustained virologic response (serum HCV RNA < 25 units/mL). In both trials, patients were randomized to ledipasvir/sofosbuvir 90 mg/400 mg orally once daily for 12 weeks vs. 24 weeks vs. ledipasvir/sofosbuvir at the same dosage plus weight-based ribavirin for 12 weeks vs. 24 weeks.
In ION-1, 870 adults (mean age 53 years, 16% with cirrhosis) were randomized and > 99% completed treatment and were included in analyses. The rates of sustained virologic response at 12 weeks after end of treatment were 99% with ledipasvir/sofosbuvir for 12 weeks, 98% with ledipasvir/sofosbuvir for 24 weeks, 97% with ledipasvir/sofosbuvir plus ribavirin for 12 weeks, and 99% with ledipasvir/sofosbuvir plus ribavirin for 24 weeks. The rate of discontinuation of ledipasvir/sofosbuvir was low in all groups: 0% with ledipasvir/sofosbuvir for 12 weeks, 2% with ledipasvir/sofosbuvir for 24 weeks, 0% with ledipasvir/sofosbuvir plus ribavirin for 12 weeks, and 3% with ledipasvir/sofosbuvir plus ribavirin for 24 weeks. The most common adverse events were fatigue, headache, insomnia, and nausea
In ION-2, 441 adults (mean age 56 years, 20% with cirrhosis) were randomized and > 99% completed treatment and were included in analyses. The rates of sustained virologic response at 12 weeks after end of treatment were 94% with ledipasvir/sofosbuvir for 12 weeks, 98% with ledipasvir/sofosbuvir for 24 weeks, 96% with ledipasvir/sofosbuvir plus ribavirin for 12 weeks, and 99% with ledipasvir/sofosbuvir plus ribavirin for 24 weeks. No patients discontinued treatment due to adverse events, and the most common adverse events were fatigue, headache, and nausea.
Sofosbuvir recently became the first drug approved by the U.S. Food and Drug Administration to treat certain types of HCV infection without coadministration of interferon (FDA Press Release 2013 Dec 6). The ION-1 and ION-2 trials demonstrate that an all-oral fixed-dose combination of ledipasvir/sofosbuvir for 12-24 weeks is associated with sustained virologic response rates > 90%, without the need for interferon or ribavirin. This was true even in patients who had not had a sustained virologic response to interferon-based therapy, a group considered more difficult to treat. These results are the basis for a new drug application for the ledipasvir/sofosbuvir combination. Other direct-acting antiviral agents have also shown promising results in early trials, and similarly are easy to administer with short duration of treatment, few contraindications, and minimal side effects reported. The arrival of these agents will almost certainly reshape the management of patients with hepatitis C infection.
However, the very high cost of treatment for these new agents (estimated to exceed $90,000 USD per course in some cases) represents a serious limitation to their use in clinical practice, particularly in developing countries. This new study does not address the issue of at what stage to initiate treatment for patients with chronic hepatitis C, but after having decided to treat with antiviral therapy, this new evidence suggests a less toxic but expensive combination can achieve very high rates of sustained virologic response.
For more information see the Hepatitis C topic in DynaMed.
Earn CME Credit for reading this e-Newsletter. For more information on this educational activity, see the CME sidebar.
May 3-7, 2014
Deputy Editor Thomas Hilts, DO, will be attending the Society of Teachers of Family Medicine (STFM) 47th Annual Spring Conference, held at the Grand Hyatt San Antonio Riverwalk in San Antonio, Texas. Representatives will be available to discuss peer review, mobile access, and free trial information.
Visit the Society of Teachers of Family Medicine website to learn more about the event and for registration information.
If you would like to meet with a DynaMed representative at any of our conferences, please contact us at DynaMedCommunity@ebscohost.com.